ABCB1 inhibitors reverse MDR by inhibiting ABCB1 transporter efflux activity or by down-regulating ABCB1 protein expression, reducing the efflux of chemotherapeutic drugs and therefore increasing drug accumulation in tumor cells (37, 38). This evidence concerns the gene ABCB1 and neoplasm.